Table 3 Top markers associated with the rate of progression from the GWAS analysis in MCI subjects^a

SNP	UCSD			ADNI			Combined
	Geno	Least-square mean estimate (24 months)	Genotype × time interaction P-value^b	Geno	Least-square mean estimate (24 months)	Genotype × time interaction P-value^b	Geno	Least-square mean estimate (24 months)	Genotype × time interaction P-value^b
rs7840202	CC	2.59	5.71E-07	CC	2.82	2.48E-05	CC	2.692	4.27E-14
	CA	0.94		CA	1.55		CA	1.192
	AA	0.66		AA	1.25		AA	0.899
rs11637611^c	CC	2.92	9.38E-10	CC	2.7	4.80E-06	CC	2.826	1.07E-15
	CT	0.78		CT	1.19		CT	0.947
	TT	0.79		TT	1.64		TT	1.138
rs12752888	CC	2.18	2.48E-10	CC	1.97	3.30E-01	CC	2.076	3.08E-11
	CT	0.92		CT	1.64		CT	1.221
	TT	0.69		TT	1.39		TT	0.992

Abbreviations: ADNI, Alzheimer's Disease Neuroimaging Initiative; CDR-SB, Clinical Dementia Rating-sum of boxes; Geno, genotype; GWAS, genome-wide association studies; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; SNP, single-nucleotide polymorphism.
^aGWAS analysis was performed with experimentally obtained genotype data using change of CDR-SB as end point and a repeated mixed model to adjust for study, baseline age, gender, baseline MMSE, baseline CDR-SB and APOE ɛ4 status (+/−).
^bNominal P<3.78 × 10⁻¹⁰ reflects genome-wide correction (1 million SNPs) for family-wide error rate of no >0.01 based on 300 000 simulations from the null distribution.
^cOther SNPs in the region (listed in Supplementary Table S1) are also strongly associated with disease progression.

Quick links

Search